242 related articles for article (PubMed ID: 26876567)
21. A quantitative multimodal metabolomic assay for colorectal cancer.
Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
[TBL] [Abstract][Full Text] [Related]
22. Metabolomics analyses of cancer tissue from patients with colorectal cancer.
Kang C; Zhang J; Xue M; Li X; Ding D; Wang Y; Jiang S; Chu FF; Gao Q; Zhang M
Mol Med Rep; 2023 Nov; 28(5):. PubMed ID: 37772396
[TBL] [Abstract][Full Text] [Related]
23. Identification of differential metabolic characteristics between tumor and normal tissue from colorectal cancer patients by gas chromatography-mass spectrometry.
Ning W; Li H; Meng F; Cheng J; Song X; Zhang G; Wang W; Wu S; Fang J; Ma K; Yang J; Pei D; Dong F
Biomed Chromatogr; 2017 Nov; 31(11):. PubMed ID: 28475217
[TBL] [Abstract][Full Text] [Related]
24. Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer.
Kim ER; Kwon HN; Nam H; Kim JJ; Park S; Kim YH
Sci Rep; 2019 Mar; 9(1):4786. PubMed ID: 30886205
[TBL] [Abstract][Full Text] [Related]
25. 1H-NMR based metabonomic profiling of human esophageal cancer tissue.
Wang L; Chen J; Chen L; Deng P; Bu Q; Xiang P; Li M; Lu W; Xu Y; Lin H; Wu T; Wang H; Hu J; Shao X; Cen X; Zhao YL
Mol Cancer; 2013 Apr; 12():25. PubMed ID: 23556477
[TBL] [Abstract][Full Text] [Related]
26. Up-regulation of type I collagen during tumorigenesis of colorectal cancer revealed by quantitative proteomic analysis.
Zou X; Feng B; Dong T; Yan G; Tan B; Shen H; Huang A; Zhang X; Zhang M; Yang P; Zheng M; Zhang Y
J Proteomics; 2013 Dec; 94():473-85. PubMed ID: 24332065
[TBL] [Abstract][Full Text] [Related]
27. Rapid diagnosis and staging of colorectal cancer via high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy of intact tissue biopsies.
Mirnezami R; Jiménez B; Li JV; Kinross JM; Veselkov K; Goldin RD; Holmes E; Nicholson JK; Darzi A
Ann Surg; 2014 Jun; 259(6):1138-49. PubMed ID: 23860197
[TBL] [Abstract][Full Text] [Related]
28. Serum metabolomics analysis for early detection of colorectal cancer.
Uchiyama K; Yagi N; Mizushima K; Higashimura Y; Hirai Y; Okayama T; Yoshida N; Katada K; Kamada K; Handa O; Ishikawa T; Takagi T; Konishi H; Kuriu Y; Nakanishi M; Otsuji E; Itoh Y; Naito Y
J Gastroenterol; 2017 Jun; 52(6):677-694. PubMed ID: 27650200
[TBL] [Abstract][Full Text] [Related]
29. Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces.
Phua LC; Koh PK; Cheah PY; Ho HK; Chan EC
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():103-13. PubMed ID: 24029555
[TBL] [Abstract][Full Text] [Related]
30. Non-invasive fecal metabonomic detection of colorectal cancer.
Phua LC; Chue XP; Koh PK; Cheah PY; Ho HK; Chan EC
Cancer Biol Ther; 2014 Apr; 15(4):389-97. PubMed ID: 24424155
[TBL] [Abstract][Full Text] [Related]
31. Tissue metabolic profiling reveals major metabolic alteration in colorectal cancer.
Shen Y; Sun M; Zhu J; Wei M; Li H; Zhao P; Wang J; Li R; Tian L; Tao Y; Shen P; Zhang J
Mol Omics; 2021 Jun; 17(3):464-471. PubMed ID: 33881127
[TBL] [Abstract][Full Text] [Related]
32. Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry.
Nishiumi S; Kobayashi T; Kawana S; Unno Y; Sakai T; Okamoto K; Yamada Y; Sudo K; Yamaji T; Saito Y; Kanemitsu Y; Okita NT; Saito H; Tsugane S; Azuma T; Ojima N; Yoshida M
Oncotarget; 2017 Mar; 8(10):17115-17126. PubMed ID: 28179577
[TBL] [Abstract][Full Text] [Related]
33. NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer.
Lin Y; Ma C; Liu C; Wang Z; Yang J; Liu X; Shen Z; Wu R
Oncotarget; 2016 May; 7(20):29454-64. PubMed ID: 27107423
[TBL] [Abstract][Full Text] [Related]
34. Metabolomics Analysis in Serum from Patients with Colorectal Polyp and Colorectal Cancer by
Gu J; Xiao Y; Shu D; Liang X; Hu X; Xie Y; Lin D; Li H
Dis Markers; 2019; 2019():3491852. PubMed ID: 31089393
[TBL] [Abstract][Full Text] [Related]
35. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer.
Yang Y; Misra BB; Liang L; Bi D; Weng W; Wu W; Cai S; Qin H; Goel A; Li X; Ma Y
Theranostics; 2019; 9(14):4101-4114. PubMed ID: 31281534
[No Abstract] [Full Text] [Related]
36. [Integrated analysis of serum untargeted metabolomics and targeted bile acid metabolomics for identification of diagnostic biomarkers for colorectal cancer].
Wang X; Zhu Y; Zhou H; Huang Z; Chen H; Zhang J; Yang S; Chen G; Zhang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):443-453. PubMed ID: 37087590
[TBL] [Abstract][Full Text] [Related]
37. Macranthoidin B Modulates Key Metabolic Pathways to Enhance ROS Generation and Induce Cytotoxicity and Apoptosis in Colorectal Cancer.
Fan X; Rao J; Zhang Z; Li D; Cui W; Zhang J; Wang H; Tou F; Zheng Z; Shen Q
Cell Physiol Biochem; 2018; 46(4):1317-1330. PubMed ID: 29689551
[TBL] [Abstract][Full Text] [Related]
38. Metabolomics and transcriptomics identify pathway differences between visceral and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study.
Liesenfeld DB; Grapov D; Fahrmann JF; Salou M; Scherer D; Toth R; Habermann N; Böhm J; Schrotz-King P; Gigic B; Schneider M; Ulrich A; Herpel E; Schirmacher P; Fiehn O; Lampe JW; Ulrich CM
Am J Clin Nutr; 2015 Aug; 102(2):433-43. PubMed ID: 26156741
[TBL] [Abstract][Full Text] [Related]
39. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
